# A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]

> **NCT00160524** · PHASE3 · COMPLETED · sponsor: **UCB Pharma SA** · enrollment: 596 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **BIOLOGICAL:** Certolizumab Pegol (CDP870)

## Key facts

- **NCT ID:** NCT00160524
- **Lead sponsor:** UCB Pharma SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 596 (ACTUAL)
- **Last updated:** 2018-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00160524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00160524, "A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00160524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*